{
    "2021-04-19": [
        [
            {
                "time": "2021-03-15",
                "original_text": "Eli Lilly And Incyteâ€™s Baricitinib Fails To Meet Endpoint In Phase 3 COVID-19 Trial",
                "features": {
                    "keywords": [
                        "Baricitinib",
                        "Phase 3",
                        "COVID-19",
                        "fails",
                        "trial"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-16",
                "original_text": "Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Bamlanivimab",
                        "End",
                        "Solo Use",
                        "COVID-19",
                        "Combo"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}